Skip to main content

Our Science The future of gene editing is now

In 2017, Beam Therapeutics was founded by gene editing pioneers with a goal of creating precision genetic medicines with base editing. Beam is a values-driven organization with a vision of delivering lifelong cures to patients suffering from serious diseases. Leveraging base editing technologies developed at Harvard University and the Broad Institute of MIT and Harvard, Beam is generating a broad pipeline of investigational precision genetic medicines that have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes without creating double-stranded cuts in DNA or RNA.

Our goal is to establish the leading platform for precision genetic medicine with a suite of gene editing and delivery technologies. Our manufacturing facility in North Carolina is under construction and anticipated to be operational in 2023.

Screen Shot 2022 04 27 At 12.25.22 PM Science Mast 2

Base Editing

Screen Shot 2022 05 11 At 2.43.54 PM

Beam has a growing portfolio of proprietary gene editing technologies, including base editing, prime editing, nuclease editing, and RNA editing. Our current base editor technology includes a cytosine base editor and an adenine base editor.

Discover More

Patients are waiting. They need cures and treatments. We believe we have the team and the technology to help deliver on that.